News
AUTL
1.320
+1.59%
0.020
Wells Fargo Reaffirms Their Buy Rating on Autolus Therapeutics (AUTL)
TipRanks · 1h ago
Autolus presents longer-term CARLYSLE lupus data at rheumatology meeting
TipRanks · 16h ago
Autolus Therapeutics Presents Longer-Term Follow Up Data From Ongoing CARLYSLE Phase 1 Trial; Data Show Clinically Significant Improvements In SLEDAI-2K Scores And Achievement Of DORIS In Most Patients Despite Severe Disease Activity At Baseline
Benzinga · 17h ago
Autolus Therapeutics reports Q3 EPS (21c), consensus (17c)
TipRanks · 21h ago
Autolus Therapeutics backs FY26 revenue view $150M, consensus $149.78M
TipRanks · 21h ago
Autolus Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 1d ago
Autolus Reports Strong Third-Quarter AUCATZYL Revenue Growth
TipRanks · 1d ago
Autolus Therapeutics GAAP EPS of -$0.21 misses by $0.03, revenue of $41.24M beats by $1.21M
Seeking Alpha · 1d ago
Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M
Benzinga · 1d ago
Autolus Therapeutics Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $41.238M Beat $39.537M Estimate
Benzinga · 1d ago
Here are the major earnings before the open Tuesday
Seeking Alpha · 1d ago
Autolus Therapeutics Q3 2026 Earnings Preview
Seeking Alpha · 2d ago
Weekly Report: what happened at AUTL last week (1102-1106)?
Weekly Report · 2d ago
Alphabet maintains massive SpaceX bet, initiates $548M Qualcomm stake
Seeking Alpha · 2d ago
Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15
Benzinga · 11/04 14:23
Autolus Therapeutics Price Target Announced at $10.00/Share by HC Wainwright & Co.
Dow Jones · 11/02 12:01
Autolus Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 11/02 12:01
HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10
Benzinga · 11/02 11:50
Autolus Therapeutics assumed with a Buy at H.C. Wainwright
TipRanks · 11/02 11:21
Weekly Report: what happened at AUTL last week (1026-1030)?
Weekly Report · 11/02 09:40
More
Webull provides a variety of real-time AUTL stock news. You can receive the latest news about AUTOLUS THERAPEUTICS PLC through multiple platforms. This information may help you make smarter investment decisions.
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.